Literature DB >> 16139132

Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease.

Ferdinando Carlo Sasso1, Daniele Torella, Ornella Carbonara, Georgina M Ellison, Michele Torella, Michelangelo Scardone, Claudio Marra, Rodolfo Nasti, Raffaele Marfella, Domenico Cozzolino, Ciro Indolfi, Maurizio Cotrufo, Roberto Torella, Teresa Salvatore.   

Abstract

OBJECTIVES: The aim of the present study was to evaluate the expression and the activity of vascular endothelial growth factor (VEGF) in the hearts of diabetic patients with chronic coronary heart disease (CHD).
BACKGROUND: Diabetes is characterized by a decreased collateral vessel formation in response to coronary ischemic events, although the role of VEGF in human diabetic macroangiopathy has not been fully investigated.
METHODS: Biopsies of left ventricular (LV) myocardium were obtained from 10 patients with type 2 diabetes and 10 non-diabetic patients with chronic CHD, all undergoing surgical coronary revascularization. Right ventricle myocardial samples taken from normal hearts were used as control specimens. Vascular endothelial growth factor and VEGF-receptors (flt-1 and flk-1) were evaluated by Western blot, reverse transcriptase-polymerase chain reaction (RT-PCR) and real-time RT-PCR. Akt and endothelial nitric oxide synthase (eNOS) protein expression and their phosphorylated forms were also evaluated by Western blot.
RESULTS: Vascular endothelial growth factor, flt-1, and flk-1 messenger ribonucleic acid (mRNA) and protein expressions were increased in non-diabetic patients with CHD compared with control subjects. Remarkably, in diabetic patients, VEGF mRNA and protein levels were significantly higher, whereas flt-1, flk-1 mRNA, and protein were lower when compared with non-diabetic patients. Interestingly, phospho-flk-1 was reduced in diabetic patients compared with non-diabetic patients. As a consequence, Akt phosphorylation, eNOS protein and its phosphorylated form were significantly higher in the samples from non-diabetic patients compared with diabetic patients.
CONCLUSIONS: Chronic CHD in diabetic patients is characterized by an increased VEGF myocardial expression and a decreased expression of its receptors along with a down-regulation of its signal transduction. The latter could be partially responsible for the reduced neoangiogenesis in diabetic patients with ischemic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139132     DOI: 10.1016/j.jacc.2005.06.007

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  66 in total

1.  Akt2 deficiency promotes cardiac induction of Rab4a and myocardial β-adrenergic hypersensitivity.

Authors:  Sharon Etzion; Yoram Etzion; Brian DeBosch; Peter A Crawford; Anthony J Muslin
Journal:  J Mol Cell Cardiol       Date:  2010-08-20       Impact factor: 5.000

2.  Selective Targeting of a Novel Epsin-VEGFR2 Interaction Promotes VEGF-Mediated Angiogenesis.

Authors:  H N Ashiqur Rahman; Hao Wu; Yunzhou Dong; Satish Pasula; Aiyun Wen; Ye Sun; Megan L Brophy; Kandice L Tessneer; Xiaofeng Cai; John McManus; Baojun Chang; Sukyoung Kwak; Negar S Rahman; Wenjia Xu; Conrad Fernandes; John Michael Mcdaniel; Lijun Xia; Lois Smith; R Sathish Srinivasan; Hong Chen
Journal:  Circ Res       Date:  2016-02-15       Impact factor: 17.367

3.  Chronic inhibition of epidermal growth factor receptor tyrosine kinase and extracellular signal-regulated kinases 1 and 2 (ERK1/2) augments vascular response to limb ischemia in type 2 diabetic mice.

Authors:  Soo-Kyoung Choi; Maria Galán; Megan Partyka; Mohamed Trebak; Souad Belmadani; Khalid Matrougui
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

4.  A ligand-independent VEGFR2 signaling pathway limits angiogenic responses in diabetes.

Authors:  Carmen M Warren; Safiyyah Ziyad; Anaïs Briot; Aaron Der; M Luisa Iruela-Arispe
Journal:  Sci Signal       Date:  2014-01-07       Impact factor: 8.192

Review 5.  Metabolic Regulation of Angiogenesis in Diabetes and Aging.

Authors:  Naoki Sawada; Zolt Arany
Journal:  Physiology (Bethesda)       Date:  2017-07

6.  State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization: A Scientific Statement From the American Heart Association.

Authors:  Michael Simons; Kari Alitalo; Brian H Annex; Hellmut G Augustin; Craig Beam; Bradford C Berk; Tatiana Byzova; Peter Carmeliet; William Chilian; John P Cooke; George E Davis; Anne Eichmann; M Luisa Iruela-Arispe; Eli Keshet; Albert J Sinusas; Christiana Ruhrberg; Y Joseph Woo; Stefanie Dimmeler
Journal:  Circ Res       Date:  2015-04-30       Impact factor: 17.367

7.  Circulating levels of endothelial progenitor cell mobilizing factors in the metabolic syndrome.

Authors:  Ishwarlal Jialal; Gian Paolo Fadini; Kari Pollock; Sridevi Devaraj
Journal:  Am J Cardiol       Date:  2010-09-21       Impact factor: 2.778

8.  Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells.

Authors:  Kazuhide Ishikura; Hirofumi Misu; Masafumi Kumazaki; Hiroaki Takayama; Naoto Matsuzawa-Nagata; Natsumi Tajima; Keita Chikamoto; Fei Lan; Hitoshi Ando; Tsuguhito Ota; Masaru Sakurai; Yumie Takeshita; Kenichiro Kato; Akio Fujimura; Ken-Ichi Miyamoto; Yoshiro Saito; Satomi Kameo; Yasuo Okamoto; Yoh Takuwa; Kazuhiko Takahashi; Hiroyasu Kidoya; Nobuyuki Takakura; Shuichi Kaneko; Toshinari Takamura
Journal:  Diabetologia       Date:  2014-07-03       Impact factor: 10.122

Review 9.  Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress.

Authors:  Munir Boodhwani; Frank W Sellke
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

10.  Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.

Authors:  Urmi Sengupta; Sanchaita Ukil; Nevenka Dimitrova; Shipra Agrawal
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.